Market Indices
Sector Heatmap
NKTR — Nektar Therapeutics
NasdaqNektar Therapeutics
- O
- 42.44
- H
- 42.44
- L
- 39.34
- V
- 1.85M
NKTR — Latest News & Headlines
20 StoriesNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Why This Biotech Took A 22% Beating On Its Alopecia Results - Investor's Business Daily
Why This Biotech Took A 22% Beating On Its Alopecia Results Investor's Business Daily
Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street
Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now? Simply Wall Street
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now? - Yahoo Finance
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now? Yahoo Finance
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking? - Barron's
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking? Barron's
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge - Stocktwits
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge Stocktwits
StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit - Genetic Engineering and Biotechnology News
StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit Genetic Engineering and Biotechnology News
NKTR Slides as Traders Appear to Sell Positive Trial Update - Quiver Quantitative
NKTR Slides as Traders Appear to Sell Positive Trial Update Quiver Quantitative
Nektar prevails in legal battle with Lilly over broken rezpeg partnership - BioSpace
Nektar prevails in legal battle with Lilly over broken rezpeg partnership BioSpace
Nektar stock tumbles on long-term alopecia data; Mabwell's T cell engager subsidiary - Endpoints News
Nektar stock tumbles on long-term alopecia data; Mabwell's T cell engager subsidiary Endpoints News
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Yahoo Finance
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly Yahoo Finance
After treatment stops, Nektar will present six-month data on severe hair loss - Stock Titan
After treatment stops, Nektar will present six-month data on severe hair loss Stock Titan
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors - Yahoo Finance
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors Yahoo Finance
Hair regrowth continued six months after treatment stopped; 19% met a stricter hair-growth target, up from 7%. - Stock Titan
Hair regrowth continued six months after treatment stopped; 19% met a stricter hair-growth target, up from 7%. Stock Titan
Hair kept regrowing for six months after treatment stopped; 19% reached a lower hair-loss score. - Stock Titan
Hair kept regrowing for six months after treatment stopped; 19% reached a lower hair-loss score. Stock Titan
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved - Yahoo Finance
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved Yahoo Finance
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. Stock Titan
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. Stock Titan
Two funds hold 9.8% of Nektar Therapeutics (NKTR), with three parties reporting the same stake. - Stock Titan
Two funds hold 9.8% of Nektar Therapeutics (NKTR), with three parties reporting the same stake. Stock Titan
A director receives an option to buy 4,000 Nektar Therapeutics (NKTR) shares at $57.66 each. - Stock Titan
A director receives an option to buy 4,000 Nektar Therapeutics (NKTR) shares at $57.66 each. Stock Titan